Job offer

Organisation/Company: Université Clermont Auvergne

Research Field: Biological sciences » Biology

Researcher Profile: Recognised Researcher (R2), Leading Researcher (R4), First Stage Researcher (R1), Established Researcher (R3)

Country: France

Application Deadline: 9 Jun 2025 - 22:00 (UTC)

Type of Contract: Temporary

Job Status: Full-time

Is the job funded through the EU Research Framework Programme? Not funded by a EU programme

Is the Job related to staff position within a Research Infrastructure? No

Offer Description

The efficacy of immunotherapy treatments aiming to stimulate the antitumor immune response is still observed only in a minority of patients. The observed resistances can be explained by an inability of immune cells to infiltrate so-called 'cold' tumors. It is urgent to identify therapeutic solutions for this type of tumor.

The administration of Targeted Radiotherapy (TRT) may be a relevant option for the treatment of cold tumors. TRT uses a vector that targets cancer cells, combined with a therapeutic radionuclide to deliver radiation specifically to the tumor. The development of TRT has been growing rapidly since the success of Luthatera and Pluvicto. A major challenge in this field is to identify new targets of interest.

This project aims to identify and validate theragnostic targets for cold tumors. We will focus on certain types of cancer, including melanoma, breast cancer, and musculoskeletal tumors. The project will be structured around 3 axes:

1. The 1st will aim to identify new tumor antigens.
2. The 2nd axis will characterize, validate, and select certain targets.
3. Axis 3 will focus on the preclinical development of TRT for selected targets.

This project will be supported by a 3-year CIR3 grant in the framework of the I-SITE program.

Début de la thèse: 01/10/2025

Funding category: Contrat doctoral

Concours pour un contrat doctoral